Press releases
-
-
-
-
-
Internal link ProQR Therapeutics Provides Update on Ophthalmic Assets
-
Internal link ProQR Announces Webcast of Presentation at the Upcoming HC Wainwright 25th Annual Global Investment Conference
-
-
-
-
-
-
-
-
Internal link ProQR Announces Initial Pipeline Targets and Highlights Axiomer® RNA Editing Platform Technology at R&D Event
-
Internal link ProQR Announces Successful Defense of a Key Axiomer® Patent Protecting ADAR-mediated RNA Editing
-
-
-
-
Internal link ProQR Announces Results for the Third Quarter of 2015 and Provides Update on Clinical Trials
-
-
-
Internal link ProQR Announces a Proof-of-Concept Nasal Potential Difference Study of QR-010 is Open for Enrollment
-
Internal link ProQR Announces Results for the Second Quarter of 2015
-
Internal link ProQR Announces Enrollment Has Started in Global Phase 1b Study of QR-010 in Cystic Fibrosis Patients
-